BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Perrigo Co. announced recently that it would recall its gProAir (Albuterol) MDI inhaler from the U.S. market due to a potential defect in the inhalers.
Perrigo’s gProAir sales were 73 million U.S. dollar in Q2 CY20.
Cipla Ltd. had acquired approval for its gProventil (Albuterol) product in April 2020.
As per our initial estimates, we had expected Cipla to record 50–60 million U.S. dollar annual sales for gProventil.
With the disruption to Perrigo’s sales, we estimate an additional 15–20 million U.S. dollar in Albuterol sales for Cipla in the U.S.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR